Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
Illumina, Inc. $750 Million Convertible Senior Notes Offering
Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by Illumina,…
Zoetis Inc. $1.5 Billion Senior Notes Offering
Davis Polk advised the joint book-running managers in connection with an SEC-registered offering by Zoetis Inc. of $300…
Davis Polk Advises ViewRay, Inc. on Its $172.5 Million Follow-On Common Stock Offering
Davis Polk advised ViewRay, Inc. in connection with its $172.5 million SEC-registered follow-on offering of 18,648,649…
NeoGenomics Follow-On Offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the…
REGENXBIO Inc. $175.5 Million Common Stock Offering
Davis Polk advised the representatives of the underwriters in connection with the $175.5 million offering of 2,700,000…
BeiGene Ltd. HK$7.08 Billion (US$903 Million) Public Offering on the Hong Kong Stock Exchange
Davis Polk advised the underwriters and the joint global coordinators in the public offering of BeiGene, Ltd. on the…
Davis Polk Advises Pernix on Private Exchange Offers
Davis Polk advised Pernix Therapeutics Holdings, Inc. in connection with separate private exchange offers for its existing…
Davis Polk Advises AC Immune SA on Its $117.5 Million Follow-On Public Offering and Subscription Rights Offerings
Davis Polk advised AC Immune SA in connection with its $117.5 million U.S. follow-on public offering. AC Immune sold 8,500…
Teladoc, Inc. $348.9 Million Common Stock Offering
Davis Polk advised the underwriter in connection with a $348.9 million SEC-registered offering of 5,263,740 shares of common…
Constellation Pharmaceuticals Initial Public Offering
Davis Polk advised the representatives of the several underwriters in connection with the $60 million initial public…